Nussbaum Ran's Form 4 filing
LB Pharmaceuticals Inc (LBRX) · filed Sep 16, 2025
- Accession no.
- 0001609805-25-000006
- Filed
- Sep 16, 2025
- Trade date
- Sep 12, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $15.0M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Nussbaum RanCIK 0001609805 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 12, 2025 | Common Stock | CConversionAcquired | +411,681 | –F1 | – | 411,681 | Indirect | |
| Sep 12, 2025 | Common Stock | PPurchaseAcquired | +1,000,000 | $15.00 | +$15,000,000 | 1,411,681 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 12, 2025 | Common Stock | CConversionDisposed | −411,681 | –F1 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.